Literature DB >> 3463540

[Bone concentrations of imipenem after a dose of imipenem/cilastatin].

D H Wittmann, T H Kuipers, R Fock, M Höll, A Bauernfeind.   

Abstract

The concentration of imipenem in organic bone, determined in 16 patients by bioassay after short infusion (15 min) of 1 g imipenem/cilastatin was 4.3 +/- 2.06 mg/kg (geometric mean +/- standard deviation, n = 13) after 45 minutes, and 2.8 +/- 1.86 mg/kg (n = 26) after 88 minutes. Imipenem penetrates into inorganic hydroxylapatite (imbution), however, its antimicrobial activity is lost. The mean serum concentration in 12 patients (mean age 77 years) with normal renal and hepatic function 15 minutes after the beginning of the infusion was 93.1 mg/l imipenem. The mean serum half life t (1/2 beta) was 1.32 hours, the total body clearance 108.6 1/h, and the volume of distribution during the beta phase V(beta) 12.4 1.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463540     DOI: 10.1007/BF01647497

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

2.  N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; N Patel
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

3.  [Pharmacokinetics of propicillin in geriatric patients in comparison with younger adults].

Authors:  C Simon; V Malerczyk; U Müller; G Müller
Journal:  Dtsch Med Wochenschr       Date:  1972-12-29       Impact factor: 0.628

Review 4.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

5.  Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

Authors:  S R Norrby; K Alestig; F Ferber; J L Huber; K H Jones; F M Kahan; M A Meisinger; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

6.  Imipenem/cilastatin in the treatment of osteomyelitis.

Authors:  R R MacGregor; L O Gentry
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

7.  Antibiotics in bone tissues. Methodological and practical aspects.

Authors:  K Dornbusch
Journal:  Scand J Infect Dis Suppl       Date:  1978

8.  Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.

Authors:  I Braveny; K Machka; R Elsser
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

9.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

10.  [Use of hydroxyapatite for determination of antibiotic concentrations in bone].

Authors:  D H Wittmann; D Berghoff; V Reynders-Frederix; H H Schassan
Journal:  Arzneimittelforschung       Date:  1983
View more
  4 in total

Review 1.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

Review 2.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 3.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Functionalization of Synthetic Bone Substitutes.

Authors:  André Busch; Marcus Jäger; Constantin Mayer; Andrea Sowislok
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.